Champions Oncology, Inc. (CSBR)

NCM – Real Time Price. Currency in USD

6.27

+0.26 (4.33%)

At close: May 12, 2026, 4:00 PM EDT

09.04.2026

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.

30.03.2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine.

12.03.2026

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

12.03.2026

Champions Oncology Reports Revenue of $16.6 Million

Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026. Third Quarter and Recent Highlights: Record study service revenue of $16.6 million, up approximately 32% year over year Total revenue of $16.6 million, compared to $17.0 million in the prior-year period Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000 The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work.

05.03.2026

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

15.12.2025

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

15.12.2025

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025. Second Quarter and Recent Highlights: Total revenue increased 11% to $15 million Oncology services profit of $7.8 million; oncology services margin of 52% Net income of $237,000 Adjusted EBITDA of $843,000 First Half 2026 Highlights: Total revenue increased 5% to $29 million Oncology services profit of $13.8 million; oncology services margin of 47% Adjusted EBITDA of $962,000 Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress.

Videos

No Data

There is no data to display

Press releases

30.03.2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

12.03.2026

Champions Oncology Reports Revenue of $16.6 Million

15.12.2025

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

23.07.2025

Champions Oncology Reports Record Annual Revenue of $57 Million

Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. Fourth Quarter Financial Highlights: Total revenue of $12.3 million Adjusted EBITDA loss of $1.2 million New data licensing revenue of approximately $200,000 Operating cash flow of $6.4 million Fiscal Year 2025 Financial Highlights: Record annual revenue of $57 million, an increase of 14% year-over-year Net income of $4.6 million Adjusted EBITDA income of $7.1 million Data license revenue of $4.7 million Year-end cash balance of $9.8 million Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation".

Champions Oncology, Inc. (CSBR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Champions Oncology, Inc. (CSBR)

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Videos

No Data

Press releases

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Champions Oncology Reports Record Annual Revenue of $57 Million

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Videos

No Data

Press releases

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Champions Oncology Reports Record Annual Revenue of $57 Million

Search stocks

Champions Oncology, Inc. (CSBR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Champions Oncology, Inc. (CSBR)

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Videos

No Data

Press releases

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Champions Oncology Reports Record Annual Revenue of $57 Million

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Videos

No Data

Press releases

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology Reports Revenue of $16.6 Million

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Champions Oncology Reports Record Annual Revenue of $57 Million